Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#51 / 151 Total
BLIV - BeLive Holdings - Stock Price Chart
TickerBLIV [NASD]
CompanyBeLive Holdings
CountrySingapore
IndustrySoftware - Application
Market Cap32.22MEPS (ttm)-0.28
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S16.70EPS next 5Y-
P/B85.95EPS Q/Q-46.31%
Dividend-Sales Q/Q-39.72%
Insider Own52.76%Inst Own-
Insider Trans0.00%Inst Trans0.00%
Short Float-Earnings-
Analyst Recom-Target Price-
Avg Volume891.42K52W Range2.80 - 6.40
Belive Holdings engages in the development of software and programming activities and provides consultancy services. The company offers technology solutions for live commerce and shoppable short videos. It offers services through BeLive White Label solution and a cloud-based BeLive software-as-a-service (SaaS) solution. The company was founded in 2014 and is headquartered in Singapore.
OCEA - Ocean Biomedical Inc - Stock Price Chart
TickerOCEA [NASD]
CompanyOcean Biomedical Inc
CountryUSA
IndustryBiotechnology
Market Cap6.89MEPS (ttm)-0.84
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B-EPS Q/Q62.02%
Dividend-Sales Q/Q-
Insider Own16.22%Inst Own2.27%
Insider Trans0.00%Inst Trans-71.61%
Short Float2.11%Earnings-
Analyst Recom1.00Target Price18.50
Avg Volume55.33M52W Range0.04 - 2.09
Mar-28-25 08:30AM Ocean Biomedical Announces Grant on Patent Right for Bispecific Antibodies Targeting CHI3L1 and PD1 for Enhanced Tumor Cell Cytotoxicity in China (GlobeNewswire) -18.46%
Feb-10-25 08:00AM Ocean Biomedical Announces Breakthrough Findings in EGFR-Mutant Lung Cancer and Plans for FDA Alignment on Next-Stage Development (GlobeNewswire) +11.36%
Jan-29-25 08:30AM Ocean Biomedical Advances Malaria Vaccine Research with New NIH Funding and Expedited Development Pathway (GlobeNewswire) -26.33%
Nov-22-24 04:45PM Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q (GlobeNewswire)
Oct-22-24 04:45PM Ocean Biomedical, Inc. Announces Receipt of Nasdaq Staff Determination Letter (GlobeNewswire)
Oct-15-24 07:30AM Molecure (WSE: MOC) and Nasdaq-listed biotechnology company Ocean Biomedical (NASDAQ: OCEA) sign an exclusive licensing agreement for the development and commercialization of selective YKL-40 inhibitors. (GlobeNewswire) +18.27%
Oct-01-24 08:01AM Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Publication of New Data Deepening Understanding of Novel Cancer Immunotherapy Treatment Approach Targeting CHI3L1 and its Ability to Inhibit Anti-tumor and Related Tissue Remodeling Responses (GlobeNewswire) -5.10%
Aug-27-24 08:01AM Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Issued for PfGARP Malaria Antibodies Central to Company's Malaria Treatment and Prevention Platforms (GlobeNewswire) -7.24%
Aug-23-24 04:30PM Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q (GlobeNewswire) -5.61%
Jun-12-24 07:46AM Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace) -10.00%
Ocean Biomedical, Inc. is a biopharmaceutical company. It engages in the business of discovering and developing therapeutic products in oncology, fibrosis, infectious diseases and inflammation. The company was founded by Chirinjeev Kathuria in June 2021 and is headquartered in Providence, RI.
EVGN - Evogene Ltd - Stock Price Chart
TickerEVGN [NASD]
CompanyEvogene Ltd
CountryIsrael
IndustryBiotechnology
Market Cap6.47MEPS (ttm)-4.45
P/E-EPS this Y30.97%
Forward P/E-EPS next Y32.33%
PEG-EPS past 5Y8.30%
P/S0.86EPS next 5Y44.28%
P/B-EPS Q/Q-61.35%
Dividend-Sales Q/Q-52.32%
Insider Own1.56%Inst Own7.10%
Insider Trans0.00%Inst Trans-25.64%
Short Float0.36%EarningsMar 06/b
Analyst Recom1.00Target Price5.50
Avg Volume21.89K52W Range0.99 - 9.00
Evogene Ltd. engages in the development and commercialization of a computer-biological platform for improving the development processes of products in the field of life sciences. It operates through the following segments: Agriculture, Industrial Applications, and Human Health. The Agriculture segment develops seed traits, agrochemical products, and agro biological products to improve plant performance. The Industrial Applications focuses on the development and commercialization of improved castor bean seeds for industrial uses. The Human Health segment involves discovery and development of human microbiome-based therapeutics. The company was founded by Amir Barzilay and Hagai Karchi on October 10, 1999 and is headquartered in Rehovot, Israel.
PLUG - Plug Power Inc - Stock Price Chart
TickerPLUG [NASD, RUT]
CompanyPlug Power Inc
CountryUSA
IndustryElectrical Equipment & Parts
Market Cap874.80MEPS (ttm)-2.52
P/E-EPS this Y76.32%
Forward P/E-EPS next Y31.97%
PEG-EPS past 5Y-49.35%
P/S1.39EPS next 5Y51.03%
P/B0.47EPS Q/Q-37.88%
Dividend-Sales Q/Q-13.81%
Insider Own6.60%Inst Own48.43%
Insider Trans-0.02%Inst Trans10.05%
Short Float30.81%EarningsMar 03/a
Analyst Recom2.86Target Price2.10
Avg Volume61.79M52W Range0.90 - 4.90
Plug Power, Inc. provides alternative energy technology, which focuses on the design, development, commercialization, and manufacture of hydrogen and fuel cell systems used primarily for the material handling and stationary power markets. Its fuel cell system solution is designed to replace lead-acid batteries in electric material handling vehicles and industrial trucks for some distribution and manufacturing businesses. The company was founded by George C. McNamee and Larry G. Garberding on June 27, 1997, and is headquartered in Slingerlands, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MCNAMEE GEORGE CDirectorNov 01 '24Sale2.0910,00020,916684,782Nov 05 04:30 PM
MSSB C/FGEORGE C MCNAMEEIRA ROOfficerNov 01 '24Proposed Sale1.9610,00019,600Nov 01 04:51 PM
MCNAMEE GEORGE CDirectorAug 01 '24Sale2.3710,00023,719683,444Aug 02 04:52 PM
MSSB C/FGEORGE C MCNAMEEIRA ROOfficerAug 01 '24Proposed Sale2.4710,00024,700Aug 01 04:25 PM
MCNAMEE GEORGE CDirectorMay 10 '24Sale2.5610,00025,576639,572May 13 04:34 PM
ABOS - Acumen Pharmaceuticals Inc - Stock Price Chart
TickerABOS [NASD, RUT]
CompanyAcumen Pharmaceuticals Inc
CountryUSA
IndustryBiotechnology
Market Cap54.56MEPS (ttm)-1.70
P/E-EPS this Y-31.08%
Forward P/E-EPS next Y26.99%
PEG-EPS past 5Y-54.87%
P/S-EPS next 5Y-2.65%
P/B0.30EPS Q/Q-117.02%
Dividend-Sales Q/Q-
Insider Own26.90%Inst Own62.14%
Insider Trans-0.89%Inst Trans-4.55%
Short Float3.74%EarningsMar 27/b
Analyst Recom1.00Target Price9.20
Avg Volume243.82K52W Range0.90 - 3.92
Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which discovers and develops medicines and diagnostics for Alzheimer's disease. The company was founded by William L. Klein, Grant A. Krafft, and Caleb Finch in 1996 and is headquartered in Charlottesville, VA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Zuga MattCFO & Chief Business OfficerJan 23 '25Sale1.7228,90249,633231,744Jan 23 09:19 PM
Zuga MattCFO & Chief Business OfficerJan 21 '25Sale1.604,3646,986260,646Jan 23 09:19 PM
OConnell Daniel JosephChief Executive OfficerJan 21 '25Sale1.5912,61920,102667,488Jan 23 05:18 PM
Meisner Derek MChief Legal Officer & Corp SecJan 21 '25Sale1.593,4185,435161,127Jan 23 05:16 PM
Barton RussellChief Operating OfficerJan 21 '25Sale1.612,9144,692136,117Jan 23 05:14 PM
SNCY - Sun Country Airlines Holdings Inc - Stock Price Chart
TickerSNCY [NASD, RUT]
CompanySun Country Airlines Holdings Inc
CountryUSA
IndustryAirlines
Market Cap472.04MEPS (ttm)0.96
P/E9.28EPS this Y46.45%
Forward P/E4.06EPS next Y42.17%
PEG0.24EPS past 5Y3.58%
P/S0.44EPS next 5Y38.71%
P/B0.83EPS Q/Q142.47%
Dividend-Sales Q/Q6.05%
Insider Own12.01%Inst Own97.53%
Insider Trans-64.67%Inst Trans10.54%
Short Float12.45%EarningsFeb 04/b
Analyst Recom1.56Target Price16.56
Avg Volume930.50K52W Range9.22 - 18.59
Sun Country Airlines Holdings, Inc. engages in the provision of scheduled passenger service, charter air transportation and, cargo businesses. Its geographical segments include Domestic and Latin America segment. The company was founded on December 8, 2017 and is headquartered in Minneapolis, MN.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Whitney GrantChief Revenue Officer & SVPApr 02 '25Sale11.3888310,04928,086Apr 03 12:44 PM
Whitney GrantChief Revenue Officer & SVPApr 01 '25Sale12.064044,87128,969Apr 03 12:44 PM
Neale Erin RoseSVP, GC, and SecretaryApr 01 '25Sale12.037989,60134,660Apr 03 12:43 PM
Mays Gregory A.Chief Operating Officer & EVPApr 01 '25Sale12.031,31915,86787,837Apr 03 12:41 PM
Gyurci JohnChief Acct. Off. & VP, FinanceApr 01 '25Sale11.983183,81017,573Apr 03 12:40 PM
NVO - Novo Nordisk ADR - Stock Price Chart
TickerNVO [NYSE]
CompanyNovo Nordisk ADR
CountryDenmark
IndustryDrug Manufacturers - General
Market Cap195.39BEPS (ttm)3.28
P/E17.69EPS this Y24.37%
Forward P/E12.15EPS next Y21.60%
PEG0.90EPS past 5Y21.74%
P/S4.64EPS next 5Y19.63%
P/B12.95EPS Q/Q28.11%
Dividend3.39%Sales Q/Q29.02%
Insider Own0.01%Inst Own10.13%
Insider Trans0.00%Inst Trans0.16%
Short Float0.44%EarningsFeb 05/b
Analyst Recom2.03Target Price108.55
Avg Volume8.64M52W Range59.32 - 148.15
Apr-17-25Downgrade BMO Capital Markets Outperform → Market Perform $64
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsvaerd, Denmark.
NTIC - Northern Technologies International Corp - Stock Price Chart
TickerNTIC [NASD, RUT]
CompanyNorthern Technologies International Corp
CountryUSA
IndustrySpecialty Chemicals
Market Cap65.66MEPS (ttm)0.39
P/E17.99EPS this Y-66.10%
Forward P/E33.00EPS next Y5.00%
PEG-EPS past 5Y-0.12%
P/S0.78EPS next 5Y-
P/B0.94EPS Q/Q-74.57%
Dividend4.04%Sales Q/Q-8.49%
Insider Own17.55%Inst Own40.79%
Insider Trans0.00%Inst Trans-0.68%
Short Float1.74%EarningsApr 10/b
Analyst Recom1.00Target Price13.00
Avg Volume25.32K52W Range7.01 - 19.63
Northern Technologies International Corp. engages in the development and marketing of proprietary environmentally beneficial products and services. It operates through the Natur-Tec and Zerust segments. The Natur-Tec segment manufactures bio-degradable and bio-based plastics for industrial and consumer applications. The Zerust segment provides corrosion mitigation solutions and services to oil, gas, and chemical processing applications. The company was founded in 1970 and is headquartered in Circle Pines, MN.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LYNCH G PATRICKPresident and CEOAug 26 '24Option Exercise10.0510,488105,404112,994Aug 29 05:47 PM
NIGON RICHARDDirectorAug 01 '24Option Exercise10.0512,000120,60045,600Aug 02 06:21 PM
von Falkenhausen KonstantinDirectorJul 31 '24Option Exercise10.058,00080,40023,200Aug 01 05:28 PM
WOLSFELD MATTHEW CCFO and Corporate SecretaryJul 15 '24Option Exercise10.057,75277,908168,149Jul 17 04:15 PM
Kemp Sarah E.DirectorApr 23 '24Buy15.701,27520,0185,760Apr 24 04:56 PM
ADTX - Aditxt Inc - Stock Price Chart
TickerADTX [NASD]
CompanyAditxt Inc
CountryUSA
IndustryBiotechnology
Market Cap283.39MEPS (ttm)-161133.90
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y83.15%
P/S2179.92EPS next 5Y-
P/B0.65EPS Q/Q99.95%
Dividend-Sales Q/Q-96.09%
Insider Own0.00%Inst Own0.03%
Insider Trans-Inst Trans0.00%
Short Float-Earnings-
Analyst Recom1.00Target Price610000.00
Avg Volume3.04M52W Range2.11 - 27200.00
Apr-17-25 09:08PM KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials (Business Wire) +13.64%
09:03PM KILL Dr. Charles Howe of the Mayo Clinics Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxts Subsidiary Adimune (Business Wire)
08:15AM Dr. Charles Howe of the Mayo Clinics Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxts Subsidiary Adimune (Business Wire)
Apr-16-25 08:15AM Aditxt Subsidiary Pearsanta Receives IRB Approval to Initiate Clinical Study of Blood-Based Diagnostic for Endometriosis with Patient Enrollment Planned to Begin in May 2025 (Business Wire) -8.71%
Apr-14-25 08:15AM Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials (Business Wire) -13.19%
Apr-11-25 08:15AM Aditxt Weekly Update to Highlight Recent Events, Including Regaining Compliance with Nasdaq Listing Requirements (Business Wire)
Apr-10-25 09:24AM Why Aditxt Inc. (ADTX) Went Down On Thursday? (Insider Monkey)
Apr-09-25 08:15AM Aditxt, Inc. (NASDAQ: ADTX) Regains Compliance with Nasdaq Listing Requirements (Business Wire) -8.81%
Apr-02-25 08:17AM Appili President and CEO, Don Cilla to Join Aditxt CEO, Amro Albanna for Aditxt Weekly Update on April 4, 2025 (GlobeNewswire) +10.62%
08:15AM Appili President and CEO, Don Cilla Will Join Aditxt Co-founder and CEO, Amro Albanna, at the Aditxt Weekly Update on April 4, 2025 (Business Wire)
Aditxt, Inc. is a biotech innovation company, which engages in the development and commercialization of technologies focusing on monitoring and modulating the immune system. Its innovation portfolio includes Adimune and AditxtScore. The company was founded by Leonard L. Bailey, Shahrokh Shabahang, and Amro Albanna on September 28, 2017 and is headquartered in Mountain View, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
HRT FINANCIAL LP10% OwnerOct 15 '24Buy1.5015,63623,45425,434Oct 17 01:58 PM
HRT FINANCIAL LP10% OwnerOct 16 '24Sale1.1725,53429,8750Oct 17 01:58 PM
FOR - Forestar Group Inc - Stock Price Chart
TickerFOR [NYSE, RUT]
CompanyForestar Group Inc
CountryUSA
IndustryReal Estate - Development
Market Cap959.29MEPS (ttm)3.30
P/E5.73EPS this Y-11.00%
Forward P/E4.71EPS next Y12.96%
PEG1.04EPS past 5Y38.51%
P/S0.65EPS next 5Y5.53%
P/B0.58EPS Q/Q-30.24%
Dividend-Sales Q/Q5.15%
Insider Own62.64%Inst Own35.61%
Insider Trans0.01%Inst Trans-0.94%
Short Float3.31%EarningsApr 17/b
Analyst Recom1.50Target Price32.25
Avg Volume215.74K52W Range18.63 - 37.21
Forestar Group Inc. is a residential lot development company, which engages in the provision of real estate business. The firm focuses on making investments in land acquisition and development to sell finished single-family residential lots to homebuilders. The company was founded in 2007 and is headquartered in Arlington, TX.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
TOMNITZ DONALD JExecutive ChairmanMar 31 '25Option Exercise0.0010,0010128,040Apr 01 05:56 PM
Walker Mark StephenChief Operating OfficerMar 31 '25Option Exercise0.002,816020,580Apr 01 05:55 PM
Allen James DouglasChief Financial OfficerMar 31 '25Option Exercise0.004,504049,839Apr 01 05:54 PM
Jamieson Lisa H.DirectorMar 31 '25Option Exercise0.00911021,859Apr 01 05:53 PM
FULLER SAMUEL RDirectorMar 31 '25Option Exercise0.00911027,359Apr 01 05:52 PM
123456789101116